Search

Displaying results 3071 - 3080 of 9322 in total
  1. Drug

    Influenza A virus A/Darwin/6/2021 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16922
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  2. Drug

    Influenza B virus B/Austria/1359417/2021 BVR-26 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16925
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  3. Drug

    Influenza A virus A/Norway/31694/2022 (H1N1) live (attenuated) antigen

    go.drugbank.com/drugs/DB18661
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  4. Drug

    Influenza A virus A/Sydney/1304/2022 (H3N2) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB19321
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  5. Drug

    Influenza A virus A/Massachusetts/18/2022 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB19322
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  6. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB19323
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  7. Drug

    Influenza A virus A/Thailand/8/2022 IVR-237 antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB19324
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  8. Drug

    Influenza A Virus A/Thailand/8/2022 IVR-237 (H3N2) whole

    go.drugbank.com/drugs/DB19413
    Approved

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

  9. Drug

    Tasosartan

    go.drugbank.com/drugs/DB01349
    Experimental

    Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.

    Categories: Agents Acting on the Renin-Angiotensin System
  10. Drug

    Dicyclomine

    go.drugbank.com/drugs/DB00804
    ApprovedInvestigational

    Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder